Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …

The widespread nature of several viruses is greatly credited to their rapidly altering RNA
genomes that enable the infection to persist despite challenges presented by host cells …

The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …

Highlights•Molnupiravir is a broad acting, oral antiviral versus SARS-CoV-2, flu, Ebola and
others.•Clinical development was greatly accelerated in response to the COVID19 …

The highly transmissible variants of SARS-CoV-2, the causative pathogen of the COVID-19
pandemic, bring new waves of infection worldwide. Identification of effective therapeutic …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

COVID-19 respiratory disease caused by the severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2) has rapidly become a global health issue since it emerged in December …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a
challenge to global health. At present, many candidate small-molecule therapeutics have …